Progress toward Health System Readiness for Genome-Based Testing in Canada.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

Publication: 2021- : Basel, Switzerland : MDPI
Original Publication: Toronto : Multimed, c1994-

Delivery of Health Care* ; Medical Assistance*; Humans ; Canada

(1) Background: Genomic medicine harbors the real potential to improve the health and healthcare journey of patients, care provider experiences, and improve the health system efficiency-even reducing healthcare costs. There is expected to be an exponential growth in medically necessary new genome-based tests and test approaches in the coming years. Testing can also create scientific research and commercial opportunities beyond healthcare decision making. The purpose of this research is to generate a better understanding of Canada's state of readiness for genomic medicine, and to provide some insights for other healthcare systems. (2) Methods: A mixed-methods approach of a review of the literature and key informant interviews with a purposive sample of experts was used. The health system readiness was assessed using a previously published set of conditions. (3) Results: Canada has created some of the established conditions, but further action needs to be taken to improve the state of readiness for genome-based medicine. The important gaps to be filled are the need for linked information systems and data integration; evaluative processes that are timely and transparent; navigational tools for care providers; dedicated funding to facilitate rapid onboarding and support test development and proficiency testing; and broader engagement with innovation stakeholders beyond care providers and patients. These findings highlight the role of the organizational context, social influence, and other factors that are known to affect the diffusion of innovation within health systems.

Value Health. 2022 Jun;25(6):869-886. (PMID: 35667778)
JAMA. 2013 Apr 10;309(14):1463-4. (PMID: 23571581)
Nat Med. 2022 Apr;28(4):658-665. (PMID: 35440717)
Int J Technol Assess Health Care. 2008 Summer;24(3):244-58; discussion 362-8. (PMID: 18601792)
Clin Med (Lond). 2019 Jul;19(4):273-277. (PMID: 31308102)
BMJ Qual Saf. 2015 Oct;24(10):608-10. (PMID: 26038586)
CMAJ. 2023 Mar 20;195(11):E413-E414. (PMID: 37072235)
Value Health. 2016 Jul-Aug;19(5):577-87. (PMID: 27565275)
Milbank Q. 2004;82(4):581-629. (PMID: 15595944)
BMJ. 2021 Sep 30;374:n2061. (PMID: 34593508)
BMC Med Res Methodol. 2009 Jul 16;9:52. (PMID: 19607668)
BMC Med Genomics. 2017 May 22;10(1):35. (PMID: 28532511)
Healthcare (Basel). 2022 Oct 19;10(10):. (PMID: 36292532)
J Health Serv Res Policy. 2010 Oct;15(4):243-50. (PMID: 20592046)
Value Health. 2019 Jan;22(1):13-20. (PMID: 30661627)
Pharmacogenomics. 2021 Feb;22(3):137-144. (PMID: 33403869)
Res Nurs Health. 2017 Feb;40(1):23-42. (PMID: 27686751)

Keywords: biomedical; clinical governance; diagnostic molecular pathology; diagnostic services; financial support; genetic services; genetic testing; health technology; healthcare innovation; technology assessment

Date Created: 20230627 Date Completed: 20230629 Latest Revision: 20230701

20230701

PMC10296918

10.3390/curroncol30060408

37366891